FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3213728081> ?p ?o ?g. }

• W3213728081 abstract "The aim of the present study was to investigate whether the degree of contrast enhancement on contrast‑enhanced (CE)‑CT can predict the prognosis of patients with hepatocellular carcinoma (HCC) treated with lenvatinib (LEN). A total of 67 consecutive patients with LEN‑treated HCC were retrospectively analysed. In the pretreatment CE‑CT, the CT values were measured using a region of interest within the main nodule and the liver parenchyma in the arterial phase, and the macroscopic degree of contrast enhancement of the tumour area was quantified by calculating the enhancement ratio (ER) of the liver parenchyma. The associations of pretreatment ER with progression‑free survival (PFS) and overall survival (OS) were then investigated. There were 20, 27 and 20 patients in the ER ≥1.5, 1.0≤ ER <1.5 and ER <1.0 groups, respectively. There was no significant difference in the PFS and OS among the three ER groups (PFS, P=0.63; OS, P=0.455). The ER <1.0 group had significantly more patients with larger tumour diameters, Barcelona Clinic Liver Cancer (BCLC) stage C with extrahepatic metastases, and higher des‑γ‑carboxy prothrombin values compared with the ER ≥1.0 group, suggesting that ER <1.0 reflected more aggressive types of HCC. The multivariate analysis revealed tumour size and α‑fetoprotein as independent predictors of shorter PFS. Albumin‑bilirubin grade 2 and BCLC stage C were significant predictors of poor OS, whereas the ER was confirmed as a non‑significant predictor of both PFS and OS. Only non‑alternating LEN and transarterial therapy (AT) were identified as independent predictors of unfavourable OS in patients with BCLC stage B HCC. Therefore, LEN has a strong therapeutic effect on HCC, regardless of the degree of contrast enhancement. Furthermore, AT may prolong the OS of LEN‑treated patients with BCLC stage B HCC, regardless of tumour vascularity." @default.
• W3213728081 created "2021-11-22" @default.
• W3213728081 creator A5003031164 @default.
• W3213728081 creator A5005361135 @default.
• W3213728081 creator A5006354271 @default.
• W3213728081 creator A5012513340 @default.
• W3213728081 creator A5013194037 @default.
• W3213728081 creator A5016855346 @default.
• W3213728081 creator A5037691579 @default.
• W3213728081 creator A5057606757 @default.
• W3213728081 creator A5074219274 @default.
• W3213728081 creator A5084839932 @default.
• W3213728081 creator A5086674791 @default.
• W3213728081 date "2021-11-14" @default.
• W3213728081 modified "2023-10-15" @default.
• W3213728081 title "Association between contrast enhancement on contrast‑enhanced CT and lenvatinib effectiveness in hepatocellular carcinoma" @default.
• W3213728081 cites W1499272627 @default.
• W3213728081 cites W1667223732 @default.
• W3213728081 cites W1848819223 @default.
• W3213728081 cites W1996703005 @default.
• W3213728081 cites W2006202974 @default.
• W3213728081 cites W2008086929 @default.
• W3213728081 cites W2016044522 @default.
• W3213728081 cites W2021805276 @default.
• W3213728081 cites W2079586464 @default.
• W3213728081 cites W2151600653 @default.
• W3213728081 cites W2153935627 @default.
• W3213728081 cites W2229932408 @default.
• W3213728081 cites W2277004004 @default.
• W3213728081 cites W2305710139 @default.
• W3213728081 cites W2509359881 @default.
• W3213728081 cites W2574943617 @default.
• W3213728081 cites W2582878252 @default.
• W3213728081 cites W2591717879 @default.
• W3213728081 cites W2612910794 @default.
• W3213728081 cites W2761293277 @default.
• W3213728081 cites W2787358630 @default.
• W3213728081 cites W2889646458 @default.
• W3213728081 cites W2945004896 @default.
• W3213728081 cites W2945667482 @default.
• W3213728081 cites W2952676090 @default.
• W3213728081 cites W2955378739 @default.
• W3213728081 cites W2963316471 @default.
• W3213728081 cites W2973111363 @default.
• W3213728081 cites W2988194539 @default.
• W3213728081 cites W2996066981 @default.
• W3213728081 cites W3004690490 @default.
• W3213728081 cites W3007851200 @default.
• W3213728081 cites W3018830751 @default.
• W3213728081 cites W3022401518 @default.
• W3213728081 cites W3082671401 @default.
• W3213728081 cites W3119233878 @default.
• W3213728081 doi "https://doi.org/10.3892/mco.2021.2442" @default.
• W3213728081 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34881028" @default.
• W3213728081 hasPublicationYear "2021" @default.
• W3213728081 type Work @default.
• W3213728081 sameAs 3213728081 @default.
• W3213728081 citedByCount "2" @default.
• W3213728081 countsByYear W32137280812022 @default.
• W3213728081 crossrefType "journal-article" @default.
• W3213728081 hasAuthorship W3213728081A5003031164 @default.
• W3213728081 hasAuthorship W3213728081A5005361135 @default.
• W3213728081 hasAuthorship W3213728081A5006354271 @default.
• W3213728081 hasAuthorship W3213728081A5012513340 @default.
• W3213728081 hasAuthorship W3213728081A5013194037 @default.
• W3213728081 hasAuthorship W3213728081A5016855346 @default.
• W3213728081 hasAuthorship W3213728081A5037691579 @default.
• W3213728081 hasAuthorship W3213728081A5057606757 @default.
• W3213728081 hasAuthorship W3213728081A5074219274 @default.
• W3213728081 hasAuthorship W3213728081A5084839932 @default.
• W3213728081 hasAuthorship W3213728081A5086674791 @default.
• W3213728081 hasBestOaLocation W32137280811 @default.
• W3213728081 hasConcept C121608353 @default.
• W3213728081 hasConcept C126322002 @default.
• W3213728081 hasConcept C143998085 @default.
• W3213728081 hasConcept C146357865 @default.
• W3213728081 hasConcept C151730666 @default.
• W3213728081 hasConcept C2776231280 @default.
• W3213728081 hasConcept C2776264508 @default.
• W3213728081 hasConcept C2777546739 @default.
• W3213728081 hasConcept C2778019345 @default.
• W3213728081 hasConcept C2778695046 @default.
• W3213728081 hasConcept C71924100 @default.
• W3213728081 hasConcept C86803240 @default.
• W3213728081 hasConcept C90924648 @default.
• W3213728081 hasConceptScore W3213728081C121608353 @default.
• W3213728081 hasConceptScore W3213728081C126322002 @default.
• W3213728081 hasConceptScore W3213728081C143998085 @default.
• W3213728081 hasConceptScore W3213728081C146357865 @default.
• W3213728081 hasConceptScore W3213728081C151730666 @default.
• W3213728081 hasConceptScore W3213728081C2776231280 @default.
• W3213728081 hasConceptScore W3213728081C2776264508 @default.
• W3213728081 hasConceptScore W3213728081C2777546739 @default.
• W3213728081 hasConceptScore W3213728081C2778019345 @default.
• W3213728081 hasConceptScore W3213728081C2778695046 @default.
• W3213728081 hasConceptScore W3213728081C71924100 @default.
• W3213728081 hasConceptScore W3213728081C86803240 @default.
• W3213728081 hasConceptScore W3213728081C90924648 @default.
• W3213728081 hasIssue "1" @default.
• W3213728081 hasLocation W32137280811 @default.

• next